BACKGROUND: There is a need to find very early markers for pre-clinical Alzheimer's disease as interventions early in the disease process are thought to be most effective. OBJECTIVE: The present study aimed to address the potential relation between cerebrospinal fluid (CSF) biomarkers and reduced cognitive function in a relatively young cohort of memory clinic patients with subjective cognitive decline. METHODS: 122 patients (mean age 63 years) with subjective cognitive decline were recruited from two university memory clinics and followed for two years. RESULTS: The main finding was that the subgroup with objective memory decline during the study period had significantly higher T-tau at baseline than the group with improved memory. Baseline CSF variables showed a trend toward more pathological values in the patients with memory decline compared to those who improved or remained stable. The baseline memory score of those who declined was significantly better than the baseline score of those who improved over two years. The general trend for the whole group was improved memory and executive test scores. There were no differences in cognitive scores based on CSF quartiles at baseline, nor were there differences in cognitive outcome for patients with early amnestic mild cognitive impairment versus average cognitive function at baseline. CONCLUSIONS: The main finding that T-tau rather than amyloid-β was associated with memory decline do not support the prevailing opinion about the chain of events assumed to take place in Alzheimer's disease. In addition, memory decline was not associated with poor baseline memory score. Thus, a memory cut-off indicating low baseline memory would not would have identified the declining group.
BACKGROUND: There is a need to find very early markers for pre-clinical Alzheimer's disease as interventions early in the disease process are thought to be most effective. OBJECTIVE: The present study aimed to address the potential relation between cerebrospinal fluid (CSF) biomarkers and reduced cognitive function in a relatively young cohort of memory clinic patients with subjective cognitive decline. METHODS: 122 patients (mean age 63 years) with subjective cognitive decline were recruited from two university memory clinics and followed for two years. RESULTS: The main finding was that the subgroup with objective memory decline during the study period had significantly higher T-tau at baseline than the group with improved memory. Baseline CSF variables showed a trend toward more pathological values in the patients with memory decline compared to those who improved or remained stable. The baseline memory score of those who declined was significantly better than the baseline score of those who improved over two years. The general trend for the whole group was improved memory and executive test scores. There were no differences in cognitive scores based on CSF quartiles at baseline, nor were there differences in cognitive outcome for patients with early amnestic mild cognitive impairment versus average cognitive function at baseline. CONCLUSIONS: The main finding that T-tau rather than amyloid-β was associated with memory decline do not support the prevailing opinion about the chain of events assumed to take place in Alzheimer's disease. In addition, memory decline was not associated with poor baseline memory score. Thus, a memory cut-off indicating low baseline memory would not would have identified the declining group.
Authors: Piotr Lewczuk; Peter Riederer; Sid E O'Bryant; Marcel M Verbeek; Bruno Dubois; Pieter Jelle Visser; Kurt A Jellinger; Sebastiaan Engelborghs; Alfredo Ramirez; Lucilla Parnetti; Clifford R Jack; Charlotte E Teunissen; Harald Hampel; Alberto Lleó; Frank Jessen; Lidia Glodzik; Mony J de Leon; Anne M Fagan; José Luis Molinuevo; Willemijn J Jansen; Bengt Winblad; Leslie M Shaw; Ulf Andreasson; Markus Otto; Brit Mollenhauer; Jens Wiltfang; Martin R Turner; Inga Zerr; Ron Handels; Alexander G Thompson; Gunilla Johansson; Natalia Ermann; John Q Trojanowski; Ilker Karaca; Holger Wagner; Patrick Oeckl; Linda van Waalwijk van Doorn; Maria Bjerke; Dimitrios Kapogiannis; H Bea Kuiperij; Lucia Farotti; Yi Li; Brian A Gordon; Stéphane Epelbaum; Stephanie J B Vos; Catharina J M Klijn; William E Van Nostrand; Carolina Minguillon; Matthias Schmitz; Carla Gallo; Andrea Lopez Mato; Florence Thibaut; Simone Lista; Daniel Alcolea; Henrik Zetterberg; Kaj Blennow; Johannes Kornhuber Journal: World J Biol Psychiatry Date: 2017-10-27 Impact factor: 4.132
Authors: Carl F Eliassen; Ivar Reinvang; Per Selnes; Ramune Grambaite; Tormod Fladby; Erik Hessen Journal: Brain Behav Date: 2017-07-28 Impact factor: 2.708
Authors: Erik Hessen; Marie Eckerström; Arto Nordlund; Ina Selseth Almdahl; Jacob Stålhammar; Maria Bjerke; Carl Eckerström; Mattias Göthlin; Tormod Fladby; Ivar Reinvang; Anders Wallin Journal: Dement Geriatr Cogn Dis Extra Date: 2017-02-02
Authors: Hanneke F M Rhodius-Meester; Hilkka Liedes; Juha Koikkalainen; Steffen Wolfsgruber; Nina Coll-Padros; Johannes Kornhuber; Oliver Peters; Frank Jessen; Luca Kleineidam; José Luis Molinuevo; Lorena Rami; Charlotte E Teunissen; Frederik Barkhof; Sietske A M Sikkes; Linda M P Wesselman; Rosalinde E R Slot; Sander C J Verfaillie; Philip Scheltens; Betty M Tijms; Jyrki Lötjönen; Wiesje M van der Flier Journal: Alzheimers Dement (Amst) Date: 2018-10-08
Authors: Ingrid S van Maurik; Rosalinde E R Slot; Sander C J Verfaillie; Marissa D Zwan; Femke H Bouwman; Niels D Prins; Charlotte E Teunissen; Philip Scheltens; Frederik Barkhof; Mike P Wattjes; Jose Luis Molinuevo; Lorena Rami; Steffen Wolfsgruber; Oliver Peters; Frank Jessen; Johannes Berkhof; Wiesje M van der Flier Journal: Alzheimers Res Ther Date: 2019-04-16 Impact factor: 6.982
Authors: Marie Eckerström; Mattias Göthlin; Sindre Rolstad; Erik Hessen; Carl Eckerström; Arto Nordlund; Boo Johansson; Johan Svensson; Michael Jonsson; Simona Sacuiu; Anders Wallin Journal: Alzheimers Dement (Amst) Date: 2017-05-16